Financial Review: Cytosorbents (CTSO) vs. Agilent Technologies (A)

Agilent Technologies (NYSE: A) and Cytosorbents (NASDAQ:CTSO) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Earnings and Valuation

This table compares Agilent Technologies and Cytosorbents’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agilent Technologies $4.47 billion 4.74 $684.00 million $2.10 31.35
Cytosorbents $9.53 million 20.92 -$11.93 million ($0.32) -21.72

Agilent Technologies has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.


Agilent Technologies pays an annual dividend of $0.53 per share and has a dividend yield of 0.8%. Cytosorbents does not pay a dividend. Agilent Technologies pays out 25.2% of its earnings in the form of a dividend.


This table compares Agilent Technologies and Cytosorbents’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agilent Technologies 15.30% 16.96% 9.43%
Cytosorbents -67.83% -233.72% -57.58%

Institutional and Insider Ownership

8.7% of Cytosorbents shares are held by institutional investors. 5.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Agilent Technologies has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Agilent Technologies and Cytosorbents, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilent Technologies 0 3 9 0 2.75
Cytosorbents 0 0 5 0 3.00

Agilent Technologies currently has a consensus price target of $69.23, indicating a potential upside of 5.16%. Cytosorbents has a consensus price target of $10.45, indicating a potential upside of 50.36%. Given Cytosorbents’ stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Agilent Technologies.


Agilent Technologies beats Cytosorbents on 9 of the 15 factors compared between the two stocks.

About Agilent Technologies

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with's FREE daily email newsletter.

Leave a Reply